Answers are grounded in this paper and cite their sources.
Metabolic disorders, such as obesity and diabetes, necessitate the discovery of novel and effective enzyme inhibitors. Alpha-glucosidase is a therapeutic target for controlling postprandial hyperglycemia. The inhibition potential of Marchantin C, was evaluated against human intestinal α-glucosidase using integrated in silico approaches in this study. Molecular docking simulations performed via AutoDock Vina revealed that Marchantin C possesses an exceptional binding affinity of -8.6 kcal/mol, significantly outperforming the clinical reference drugs acarbose (-6.3 kcal/mol) and miglitol (-5.0 kcal/mol). Notably, the binding energy of Marchantin C was also superior to the native-fixed pose of acarbose (-7.8 kcal/mol), confirming its high thermodynamic stability within the catalytic pocket. Interaction analysis demonstrated that Marchantin C effectively targets the enzyme's catalytic centre, forming crucial bonds with residues Asp203 and Thr205, supplemented by Pi-Pi stacking with Trp406. Furthermore, ADMET and pharmacokinetic profiling via SwissADME indicated that Marchantin C exhibits high gastrointestinal absorption and a favourable drug-likeness profile, adhering to Lipinski's Rule of Five. Visualisation through BOILED-Egg and bioavailability radar plots further supported its potential as an orally active agent. These findings provide strong computational evidence that Marchantin C is a promising natural lead compound for managing obesity and type 2 diabetes, warranting further in vivo investigations.
No takes yet. Share an insight, caveat, or question.
Ergin Murat Altuner (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: